LDMC with DOX increased REDD1 expression in CD31+ tumor vessels only in the WT mice (Fig. 5d, e), consequently inhibiting tumor endothelial VEGFR-2 expression in the WT but not Redd1−/− mice (Fig. 5f, g); however, DOX treatment did not significantly alter serum VEGF levels in the tumor-bearing WT and Redd1−/− mice (Supplementary Fig. 7). The gene discussed is VEGFA; the disease is neoplasm.